摘要:
The present invention relates to a process for the preparation of compounds of the general Formula I ##STR1## (wherein A is a straight or branched chain alkylene group having 1-5 carbon atoms;B is ethylene, Z or E vinylene, or ethynylene;R.sup.1 stands for hydrogen, an alkyl group having 1-5 carbon atoms or a pharmaceutically acceptable cation;R.sup.2 is hydrogen, an alkanoyl group having 1-5 carbon atoms or aroyl;R.sup.3 is hydrogen or methyl;R.sup.4 is a straight or branched chain alkyl group having 1-8 carbon atoms or an optionally monosubstituted aryloxymethyl group;R.sup.5 stands for hydrogen or an alkyl group having 1-5 carbon atoms)which comprises oxidizing a compound of the Formula III, IV or V ##STR2## or a mixture thereof R.sup.6 is hydrogen or an alkyl or alkanoyl group having 1-5 carbon atoms with a mild electrophilic oxidizing agent and if desired reacting the compound of the Formula I thus obtained wherein R.sup.5 is hydrogen with an alkanol containing 1-5 carbon atoms in the presence of boron trifluoride etherate in a manner known per se to yield the corresponding compound of the Formula I in which R.sup.5 is an alkyl group having 1-5 carbon atoms.
摘要翻译:本发明涉及制备通式Ⅰ(I)化合物的方法(其中A是具有1-5个碳原子的直链或支链亚烷基; B是乙烯,Z或E亚乙烯基, 或亚乙炔基; R 1表示氢,具有1-5个碳原子的烷基或药学上可接受的阳离子; R 2是氢,具有1-5个碳原子的烷酰基或芳酰基; R 3是氢或甲基; R 4是直链或 具有1-8个碳原子的支链烷基或任选的单取代的芳氧基甲基; R 5代表氢或具有1-5个碳原子的烷基),其包括将式III,IV或V的化合物(III (V)或其混合物R6是氢或具有1-5个碳原子的烷基或烷酰基,具有温和的亲电氧化剂,如果需要,则使式I的化合物反应 其中R5是含有1-5个碳原子的链烷醇 原子在三氟化硼乙醚合物存在下,以本身已知的方式得到相应的式I化合物,其中R 5为具有1-5个碳原子的烷基。
摘要:
A process for the preparation of bicyclic enon compounds in which a lactone diol is selectively oxidized to obtain a hydroxy-aldehyde with one hydroxyl group and, without isolation, the hydroxy-aldehyde is reacted with a phosphorus compound. The reaction product can be acylated or silylated.
摘要:
A process for the preparation of optically active or racemic lactone diol derivatives of the formula ##STR1## (for use as intermediates in the Corey prostaglandin synthesis). Optically active or racemic lactone diol derivatives are inclosed, in whichR.sup.3 and R.sup.4 are the same or different and stand for a hydrogen, or a lower alkanoyl optionally substituted with one, two or three halogen atoms, or form together a ##STR2## group, in which R.sup.5 and R.sup.6 are the same or different and stand for a hydrogen, alkyl or aryl, with a process for preparing them.According to the invention the above compound are prepared by reacting optically active or racemic lactone of the formula II with formaldehyde or with a formaldehyde polymerisate, in the presence of the mixture of a strong acid and water or of a lower alkane carboxylic acid optionally substituted with one, two or three halogen atoms, and then optionally subjecting the obtained compound of the general formula I, in which R.sup.3 and/or R.sup.4 stand for an alkanoyl optionally substituted with one, two or three halogen atoms to partial or total hydrolysis or alcoholysis in an acid or alkaline medium and/or reacting it with the oxo-compounds of the formula R.sup.5 --CHO or R.sup.6 --CO--R.sup.5 or with the acetals of the above compounds.The compounds according to the invention are useful intermediates in the Corey prostaglandine synthesis.
摘要:
A compound of the formula is disclosed. ##STR1## wherein R.sup.3 and R.sup.4 are the same or different and are each hydrogen, lower alkanoyl, lower alkanoyl substituted by 1, 2, or 3 halogen atoms, or R.sup.3 and R.sup.4 together form an ##STR2## group in which R.sup.5 and R.sup.6 are the same or different and are each hydrogen, alkyl or aryl as well as a process for the preparation thereof.
摘要:
The invention relates to new 2,3,4-trinor-1,5-inter-m-phenylene-PGI.sub.2 derivatives of the formula (I) ##STR1## wherein A stands for carboxy, cyano, tetrazolyl or --COOR.sup.3 or --CONR.sup.1 R.sup.2 ;R.sup.3 is C.sub.1-4 alkyl or an equivalent of a pharmacologically acceptable cation:R.sup.1 and R.sup.2 each stands for hydrogen, phenyl; C.sub.1-5 alkyl, optionally substituted by carboxy, hydroxy, phenyl or C.sub.2-5 alkoxycarbonyl; or C.sub.1-4 alkylsulfonyl; orR.sup.1 and R.sup.2 together form an .alpha.,.omega.-alkylene chain containing 3-6 carbon atoms;B stands for oxygen or methylene;Y is optionally bromo-substituted vinylene or a --C.tbd.C-- group:R.sup.4 stands for hydrogen or tetrahydro-pyran-2-yl;R.sup.5 represents an alkyl group containing 5-9 carbon atoms, which can be optionally interrupted by one or more oxygen atom(s) or --CH.dbd.CH-- or --C.tbd.C-- group(s) and/or optionally substituted by halogen; or a phenyoxymethyl group optionally substituted by halogen or trifluoromethyl; or an alkenoyloxymethyl group containing 3-5 carbon atoms;R.sup.6 is hydrogen or C.sub.1-4 alkyl;R.sup.7 stands for hydrogen, halogen, cyano, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;R.sup.8 is hydrogen, halogen, cyano, nitro, hydroxy or C.sub.2-5 alkanoylamido;with the proviso that ifR.sup.5 stands for an alkyl group containing 5-9 carbon atoms which is unsubstituted or not interrupted by an oxygen atom or a --CH.dbd.CH-- or --C.tbd.C-- group; or a phenyoxymethyl group optionally substituted by halogen or trifluoromethyl, theneither R.sup.7 or R.sup.8 is other than hydrogen, or A is other than carboxy or --COOR.sup.3 and a process for the preparation thereof.The new compounds of the Formula I exhibit prolonged cytoprotecting and aggregation inhibiting and a low hypotensive effect and are superior to prostacycline in the prolonged duration of their activity.
摘要:
2,3,4-trinor-1,5-inter-m-phenylene-prostacycline derivatives of the formula (I), ##STR1## wherein R.sup.1 is hydrogen, a C.sub.1-4 alkyl group, an alkali metal cation or a primary, secondary, tertiary or quaternary ammonium cation,R.sup.2 and R.sup.3 each represent hydrogen or a C.sub.1-4 alkanoyl, benzoyl, substituted benzoyl, tetrahydropyranyl, ethoxyethyl or tri-(C.sub.1-4 alkyl)-silyl group,R.sup.4 is hydrogen or a C.sub.1-4 alkyl group, andR.sup.5 is a hexyl, heptyl, phenoxymethyl or m-trifluoromethylphenoxymethyl group, orR.sup.5 represents a group of the general formula ##STR2## and in this latter formula Z is an amino group or an optionally halo-substituted C.sub.1-4 alkanoylamino, benzoylamino or tosylamino group, andR.sup.6 is a C.sub.4-6 alkyl, phenyl or benzyl group,are prepared by reacting a bicyclic lactol of the formula (II), ##STR3## with a reactive phosphorane prepared from a triphenyl-m-carbobenzylphosphonium halide and a strong base, optionally esterifying the resulting prostaglandin derivative and, whenever it contains a free amino group, protecting this amino group by acylation, reacting then the prostaglandin derivative with an electrophilic reagent of the formula E-X, wherein X is halogen atom and E is halogen atom or an acetyl, trifluoroacetyl or N-succinimido group, and subjecting the resulting halogenated PGI.sub.1 derivative to hydrogen halide elimination. The compounds of the formula (I) possess valuable biological effects and can be applied in therapy primarily as blood platelet aggregation inhibiting agents.
摘要:
The invention relates to a process for the preparation of novel 4-oxo-PGI.sub.2 derivatives of formula I ##STR1## where (a) compounds of formula III ##STR2## are oxidized, then the obtained 5-substituted-4-oxo-PGI.sub.1 derivatives of general formula II ##STR3## are eliminated by the splitting off of the W-H-molecule, or (b) the compounds of formula IV ##STR4## are reacted in a solvent in the presence of a catalyst with compounds of general formula V ##STR5## then the obtained compounds of formula I are transformed if desired by saponification, hydrolysis, salt formation, insertion of a protection group to another compound which belongs to the compounds of formula I, too.The pharmaceutical products of the invention can be used for the treatment of circulatory diseases, they inhibit the aggregation of blood plaques, dilate the bronchi and inhibit the secretion of gastric acid.
摘要:
A process is disclosed for the preparation of an optically active or racemic cyclopropanecarboxylic acid of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each is lower alkyl or halogen;R is a member of a group which contains various cyclic structures as set forth in the specification,the .about. valency bond represents .alpha.- and/or .beta.-configuration;the -- valency bond represents .beta.-configuration,which comprises reacting an optically active or racemic cyclopropanecarboxylic acid of the formula (VII) ##STR2## with a dimethyl-methylidene-ammonium salt of the formula (VIII) ##STR3## wherein X is halogen or lower alkoxy andY.sup.- is a halide or lower alkylsulfate ion in an anhydrous, inert organic solvent, and sebsequently reacting a dimethyl-acloxy-methylidene-ammonium salt thus obtained with an optically active, inactive or racemic alcohol of the formulaR--OHwithout isolation, in the presence of an organic base.
摘要:
The invention relates to new, 7-substituted PGI.sub.2 -derivatives of formula (I) ##STR1## The new compounds have valuable therapeutical properties, and in particular show prostacyclin-like effects.
摘要:
A method of making an insecticidal pyrethrin by oxidation in aprotic organic solvent. The compounds are of the formula: ##STR1## wherein R.sup.11 is straight or branched chain lower alkyl or 1-alkenyl or hydrogen;R and R.sup.12 are the same or different and are hydrogen, halogen or lower alkyl or one of the moieties R and R.sup.12 is lower alkoxycarbonyl.